Theravance Announces Data on Novel Anesthesia Program
Theravance Announces Data on Novel Anesthesia Program
Nov 24, 2003
Theravance Announces Data on Novel Anesthesia ProgramSOUTH SAN FRANCISCO, Calif., November 24, 2003 /PRNewswire/ -- Theravance, Inc., today announced that results from a study with its investigational intravenous pharmacokinetically-responsive sedative hypnotic THRX-918661 were recently presented at the 2003 Meeting of the American Society of Anesthesiologists Annual Meeting in San Francisco. The study, conducted by Dr. Talmage Egan of the University of Utah School of Medicine, demonstrated the compound's rapid and predictable offset in animal models.
These data build on results presented at the meeting of the UK Society for Intravenous Anesthesia earlier this year, where Theravance scientists presented the in vivo and in vitro activity of the compound, the first in a new class of pharmacokinetically responsive agents. These results demonstrated that, in animal models, THRX-918661 is a rapidly metabolized, positive allosteric modulator of the GABAA receptor with more rapid and predictable recovery from hypnosis than propofol (Diprivan®). This work was selected at the meeting to receive the Graseby Prize, awarded to the best abstracts of the meeting by the Society.
Theravance is a privately-held pharmaceutical company dedicated to utilizing its proprietary multivalent technology to discover, develop and market best-in-class medicines for a wide variety of medical conditions. Since its inception, Theravance has implemented an integrated model of drug discovery and exploratory development and applied its multivalent approach to create an impressive pipeline of clinical and pre-clinical compounds across diverse therapeutic areas. For more information, please visit the company's web site at www.Theravance.com.
THERAVANCE™ and the THERAVANCE™ LOGO are trademarks of Theravance, Inc.
Inquiries: Media inquiries: David Brinkley 650-808-3718
These data build on results presented at the meeting of the UK Society for Intravenous Anesthesia earlier this year, where Theravance scientists presented the in vivo and in vitro activity of the compound, the first in a new class of pharmacokinetically responsive agents. These results demonstrated that, in animal models, THRX-918661 is a rapidly metabolized, positive allosteric modulator of the GABAA receptor with more rapid and predictable recovery from hypnosis than propofol (Diprivan®). This work was selected at the meeting to receive the Graseby Prize, awarded to the best abstracts of the meeting by the Society.
Theravance is a privately-held pharmaceutical company dedicated to utilizing its proprietary multivalent technology to discover, develop and market best-in-class medicines for a wide variety of medical conditions. Since its inception, Theravance has implemented an integrated model of drug discovery and exploratory development and applied its multivalent approach to create an impressive pipeline of clinical and pre-clinical compounds across diverse therapeutic areas. For more information, please visit the company's web site at www.Theravance.com.
THERAVANCE™ and the THERAVANCE™ LOGO are trademarks of Theravance, Inc.
Inquiries: Media inquiries: David Brinkley 650-808-3718